# Lightyellow Module Run: Discovery Output (19-analyte, dev, 2026-06-23)

This document presents the discovery output of a full-module run of the **Lightyellow** WGCNA module through the Kraken 12-node discovery pipeline, executed on the dev environment on 2026-06-23 (commit `813fc3f`) with BioMapper entity resolution enabled. It is one of a per-module series over the Frailty multi-omics WGCNA modules; see the [BioMapper: Collection Index](https://phwiki.phenoma.ai/doc/biomapper-collection-index-UcTfYSTchm).

## Run Provenance

The run submitted 19 named analytes, parsed 19 at intake, and resolved 19 distinct entities (17 biomapper, 2 fuzzy) to 19 distinct CURIEs. Triage classified 9 well-characterized, 3 moderate, 6 sparse, and 1 cold-start, with 0 edge-count measurement failures. Downstream analysis produced 1011 direct-KG findings, 39 cold-start findings, 4 biological themes, 20 cross-entity bridges (19 evidence-grounded), and 96 hypotheses supported by 37 literature references. Synthesis emitted a 28694-character report. The run completed in approximately 588.3 s of wall-clock time (status complete, 7 errors). All counts are taken from the reducer-merged pipeline state.

| Stage | Result |
|---|---|
| Submitted | 19 named analytes |
| Intake | 19 parsed |
| Entity resolution | 19 resolved (17 biomapper, 2 fuzzy) to 19 distinct CURIEs |
| Triage | 9 well-characterized, 3 moderate, 6 sparse, 1 cold-start (0 measurement failures) |
| Direct KG | 1011 findings |
| Cold-start | 39 findings, 1 skipped |
| Pathway enrichment | 4 biological themes |
| Integration | 20 bridges (19 evidence-grounded) |
| Literature grounding | 37 papers |
| Synthesis | 96 hypotheses, 28694-character report |
| Run total | ~588.3 s wall-clock, status complete, 7 errors |

## Related

- Companion run metrics: [Lightyellow Module Run: Pipeline Performance Report](https://phwiki.phenoma.ai/doc/lightyellow-module-run-pipeline-performance-report-19-analyte-dev-2026-06-23-WFgy5WFfxw)
- [BioMapper: Collection Index](https://phwiki.phenoma.ai/doc/biomapper-collection-index-UcTfYSTchm)

---



## Lightyellow WGCNA Module: Glutathione Catabolism, Innate Immune Alarmin Signaling, and Vascular Homeostasis

### 1. Executive Summary

The Lightyellow WGCNA module encodes a coordinated biological program linking active glutathione catabolism and sulfur amino acid cycling to an innate immune alarmin axis (IL1A, IL5, TSLP) and vascular homeostatic regulation via ADAMTS13. [KG Evidence] [Inferred] The metabolite composition reveals a signature of net oxidative stress characterized by glutathione breakdown products (cysteinylglycine, cysteine-glutathione disulfide, 5-oxoproline) and transsulfuration intermediates (S-adenosylhomocysteine, cysteine s-sulfate), while the cytokine components implicate epithelial barrier inflammation and type 2-adjacent immune activation rather than classical adaptive Th2 immunity. [KG Evidence] [Inferred] The convergence of these pathways on coronary artery disease (5 members), schizophrenia (5 members), and colorectal cancer (5 members) at the module level suggests that the module captures a systemic inflammatory-metabolic state with relevance to cardiometabolic, neuropsychiatric, and neoplastic phenotypes. [KG Evidence]

### 2. Key Findings (Tier 1 to 2)

#### 2.1 Module-Level Disease Convergence

The module-level disease recurrence analysis identified three conditions each shared by 5 of 19 members, representing the strongest cross-entity convergence:

- **Coronary artery disease** (MONDO:0005010): shared by pyruvate, lactate, IL1A, IL5, and TSLP (strongest evidence: curated). [KG Evidence] The co-occurrence of glycolytic end products (pyruvate, lactate) with pro-inflammatory cytokines in this association is consistent with the metabolic reprogramming observed in atherosclerotic plaques. [Model Knowledge]
- **Schizophrenia** (MONDO:0005090): shared by ornithine, 5-oxoproline, lactate, IL5, and TSLP (strongest evidence: curated). [KG Evidence] The inclusion of amino acid and gamma-glutamyl cycle metabolites alongside immune mediators aligns with emerging evidence for immune-metabolic dysregulation in neuropsychiatric disease. [Model Knowledge]
- **Colorectal cancer** (MONDO:0005575): shared by pyruvate, ornithine, 5-oxoproline, 3-ureidopropionate, and lactate (strongest evidence: curated). [KG Evidence] Notably, this association is driven entirely by the metabolite members of the module, suggesting a metabolic rather than cytokine-driven link to gastrointestinal neoplasia.

Additional disease associations at lower recurrence but with mechanistic coherence include:

- **Hemolytic-uremic syndrome** (MONDO:0001549): shared by ADAMTS13 and IL1A (curated). [KG Evidence] This association is mechanistically anchored by the role of ADAMTS13 in cleaving von Willebrand factor (VWF); ADAMTS13 deficiency is the established cause of thrombotic thrombocytopenic purpura, a condition closely related to hemolytic-uremic syndrome. [KG Evidence] [Model Knowledge]
- **Myocardial infarction** (MONDO:0005068): shared by lactate and ADAMTS13 (curated). [KG Evidence] Cross-type bridge analysis confirmed a 2-hop path from ADAMTS13 to lactate through myocardial infarction (biolink:gene_associated_with_condition → biolink:contraindicated_in), indicating that the ADAMTS13-lactate co-expression may be mediated by shared cardiovascular pathophysiology. [KG Evidence]
- **Atopic eczema** (MONDO:0004980): shared by lactate, IL5, and TSLP (curated). [KG Evidence] This finding reinforces the epithelial barrier/alarmin immune axis captured by the module.

**Hub bias caveat**: IL1A (5,816 edges) exceeds the hub threshold (>1,000 edges) and contributes to many of the disease associations listed above, including hiatus hernia, chronic rhinitis, necrotizing ulcerative gingivitis, gastroduodenitis, and several UMLS-coded conditions shared only among IL1A, IL5, and TSLP. [KG Evidence] These three-member associations involving IL1A should be interpreted with caution, as they may reflect IL1A's high connectivity rather than biologically meaningful module-level convergence. [Inferred]

#### 2.2 Pathway Convergence

The module-level pathway recurrence analysis reveals two principal biological programs:

**Immune and cytokine signaling (protein members):**
- Cytokine-mediated signaling pathway (GO:0019221): IL1A, IL5, TSLP (3 members). [KG Evidence]
- Hemopoiesis (GO:0030097): IL1A, IL5, TSLP (3 members). [KG Evidence]
- Inflammatory response (GO:0006954): IL1A, IL5 (2 members). [KG Evidence]
- Positive regulation of interleukin-6 production (GO:0032755): IL1A, TSLP (2 members). [KG Evidence]
- Cell-cell signaling (GO:0007267): IL1A, IL5, NRTN, TSLP (4 members). [KG Evidence]

**Glutathione and gamma-glutamyl cycle metabolism (metabolite members):**
- Glutathione metabolic process (GO:0006749): ornithine, 5-oxoproline, cysteinylglycine (3 members). [KG Evidence]
- Glutathione Synthetase Deficiency pathway (SMPDB:SMP0000337): 5-oxoproline, cysteinylglycine (2 members). [KG Evidence]
- Gamma-glutamyltransferase Deficiency pathway (SMPDB:SMP0000183): 5-oxoproline, cysteinylglycine (2 members). [KG Evidence]
- 5-Oxoprolinuria pathway (SMPDB:SMP0000143): 5-oxoproline, cysteinylglycine (2 members). [KG Evidence]

**Stress response and environmental exposure (cross-type):**
- Response to stress (GO:0006950): ADAMTS13, IL5, NRTN, TSLP (4 members). [KG Evidence]
- Smoking (UMLS:C0037369): ADAMTS13, IL5, NRTN, TSLP (4 members). [KG Evidence] The association of 4 of the 5 protein members with smoking exposure is notable and may indicate that this module is responsive to environmental oxidant exposures.

#### 2.3 Cross-Type Bridges

The analysis identified several high-confidence (Tier 2) multi-hop paths connecting the protein and metabolite compartments of the module:

- **IL1A → lactate (1-hop direct interaction)**: IL1A directly interacts with lactate in the knowledge graph (biolink:interacts_with). [KG Evidence] This finding is strongly supported by literature demonstrating that lactic acid fermentation is required for NLRP3 inflammasome activation and IL-1 family cytokine processing (Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation, 2021; Lactic acid drives NLRP3 inflammasome activation, 2026). [Literature] The direct bridge between IL1A and lactate provides the most mechanistically compelling link between the immune and metabolic arms of the module.
- **ADAMTS13 → ornithine (2-hop via ALDH18A1)**: ADAMTS13 physically interacts with ALDH18A1, which in turn affects ornithine biosynthesis (biolink:directly_physically_interacts_with → biolink:affects). [KG Evidence] ALDH18A1 (also known as P5CS) catalyzes the conversion of glutamate to Δ1-pyrroline-5-carboxylate, a precursor in proline and ornithine biosynthesis. [Model Knowledge] This path suggests a functional link between ADAMTS13 and amino acid metabolism that warrants further investigation.
- **ADAMTS13 → lactate (2-hop via disease nodes)**: Multiple 2-hop paths connect ADAMTS13 to lactate through shared disease associations (myocardial infarction, kidney disorder, acidosis, cardiovascular disorder, stroke). [KG Evidence] These convergent paths through distinct disease intermediaries strengthen the inference that ADAMTS13 and lactate co-expression reflects shared vascular/metabolic pathophysiology rather than coincidence. [Inferred]
- **IL1A → cysteinylglycine (2-hop via cytoplasm and extracellular region)**: Shared subcellular localization links IL1A to cysteinylglycine via both cytoplasmic and extracellular compartments. [KG Evidence] Notably, a 2025 study (Extended Data Fig. 5, Nature Metabolism) reports pathway-level analysis of cysteine-containing peptides and metabolites altered following IL-1α stimulation, providing direct experimental support for a functional link between IL1A signaling and cysteine-derived metabolite flux. [Literature]

#### 2.4 Member Prioritization Highlights

The Member Prioritization Table identifies the highest-leverage individual members:

| Priority | Member | Rationale |
|---|---|---|
| Highest | IL1A | Hub node (5,816 edges); participates in the most disease and pathway associations; direct bridge to lactate; hub bias warning applies. [KG Evidence] |
| High | IL5 | Key type 2 immune cytokine (3,200 edges); top disease: asthma; shared pathway memberships with TSLP. [KG Evidence] |
| High | ADAMTS13 | Vascular metalloprotease (2,517 edges); unique disease space (thrombotic thrombocytopenic purpura); multiple bridges to metabolite members. [KG Evidence] |
| High | 5-oxoproline | Central gamma-glutamyl cycle metabolite (404 edges); connects to cysteinylglycine in 5 shared disease/pathway annotations. [KG Evidence] |
| Moderate | NRTN | Neurotrophic factor (1,454 edges); top disease: Hirschsprung disease; provides the neuronal dimension to the module. [KG Evidence] |
| Low | Sparse/cold-start metabolites | Pyroglutamyl-dipeptides, cysteine-glutathione disulfide, SAH, 1-palmitoylglycerol, 3-amino-2-piperidone have limited KG representation but contribute to biological theme coherence. [KG Evidence] |

### 3. Novel Predictions (Tier 3)

*Approximately 18% of computational predictions of this type progress to clinical investigation; all findings below require experimental validation.*

#### 3.1 Cysteine-Glutathione Disulfide as a Glutathione S-Transferase Substrate

**Prediction**: Cysteine-glutathione disulfide (CHEBI:21264) physically interacts with GSTP1 and GSTA1. [Inferred]

**Logic chain**: Cysteine-glutathione disulfide is structurally similar (0.78) to S-hydroxy-L-cysteine (CHEBI:41710). S-hydroxy-L-cysteine physically interacts with GSTP1 (NCBIGene:2950) and GSTA1 (NCBIGene:2938) in the KG. [KG Evidence] Both are glutathione S-transferase family members whose canonical function involves glutathione conjugation; the glutathione moiety present in cysteine-glutathione disulfide makes enzymatic processing by GSTs biochemically plausible. [Model Knowledge] No direct KG evidence or grounded literature links cysteine-glutathione disulfide specifically to these enzymes in the current analysis.

**Validation step**: Test cysteine-glutathione disulfide as a substrate in recombinant GSTP1 and GSTA1 enzymatic assays; query redox proteomics datasets for evidence of GST-mediated processing of mixed glutathione disulfides.

**~18% calibration**: This prediction rests on a single analogue (similarity 0.78) with shared thiol-reactive chemistry; the structural justification is moderate, placing this prediction at the higher end of the ~18% prior for computational-to-clinical progression.

#### 3.2 Pyroglutamylvaline Association with Colorectal Cancer

**Prediction**: Pyroglutamylvaline (CHEBI:132991) is correlated with colorectal cancer (MONDO:0005575). [Inferred]

**Logic chain**: Pyroglutamylvaline is structurally similar to pyroglutamylglutamine (0.84) and Val-Glu (0.78), both of which are related to or correlated with colorectal cancer in the KG. [KG Evidence] Two independent structural analogues converge on the same disease, strengthening this inference. [Inferred] Colorectal cancer is independently associated with 5 module members at the module level (pyruvate, ornithine, 5-oxoproline, 3-ureidopropionate, lactate). [KG Evidence]

**Validation step**: Search metabolomics databases (HMDB, MetaboAnalyst) and published metabolomics studies for pyroglutamylvaline abundance in colorectal cancer cohorts relative to controls.

**~18% calibration**: The convergence of two analogues on the same disease entity and the independent module-level recurrence of colorectal cancer elevate confidence modestly above the ~18% baseline, though the analogues share the pyroglutamyl-dipeptide scaffold and therefore may not represent truly independent evidence.

#### 3.3 1-Palmitoylglycerol in Ether Lipid and Glycerophospholipid Metabolism

**Prediction**: 1-Palmitoylglycerol (CHEBI:63582) participates in Reactome ether lipid/glycerophospholipid metabolism pathways (R-HSA-390427, R-HSA-75879) and may interact with AGPS (alkylglycerone phosphate synthase, NCBIGene:8540). [Inferred]

**Logic chain**: 1-palmitoylglycerol is structurally similar (0.97) to 1-palmitoylglycerone 3-phosphate (CHEBI:58303), which serves as input to Reactome reaction R-HSA-390427 and as output of conserved biosynthetic reactions (R-BTA-75879, R-MMU-75879, R-CFA-75879). [KG Evidence] AGPS physically interacts with the structurally similar 1-palmitylglycerone 3-phosphate (CHEBI:77429, similarity 0.95). [KG Evidence] No grounded literature was fetched for these specific connections.

**Validation step**: Query Reactome for 1-palmitoylglycerol participation in glycerolipid metabolism; test 1-palmitoylglycerol as a substrate in AGPS enzymatic assays or competitive binding assays.

**~18% calibration**: The very high structural similarity (0.95 to 0.97) between 1-palmitoylglycerol and its analogues is unusually strong for cold-start inference, but the prediction involves ontological classification rather than a mechanistic interaction, placing it at the ~18% baseline.

#### 3.4 Informative Absences as Predictive Signals

Several expected-but-absent entities generate Tier 3 hypotheses through the Open World Assumption:

- **Glutathione (GSH) absence**: The module contains cysteinylglycine, cysteine-glutathione disulfide, cysteine s-sulfate, and 5-oxoproline, all of which are products of glutathione catabolism via gamma-glutamyl transpeptidase (GGT). [Model Knowledge] The absence of intact glutathione while its degradation products co-express strongly suggests a state of net glutathione catabolism, consistent with active oxidative stress or rapid gamma-glutamyl cycle turnover. [Inferred]
- **Homocysteine and free cysteine absence**: S-adenosylhomocysteine (SAH) is present while homocysteine is absent; multiple cysteine conjugates are present while free cysteine is absent. [KG Evidence] This pattern suggests efficient transsulfuration flux (SAH → homocysteine → cysteine → glutathione) with rapid consumption of intermediates rather than accumulation. [Inferred] [Model Knowledge]
- **IL-4/IL-13 absence**: IL5 and TSLP are present, but the canonical Th2 cytokines IL-4 and IL-13 are absent. [KG Evidence] This dissociation may indicate that the module captures a TSLP-driven epithelial/innate alarmin response rather than classical adaptive Th2 immunity. [Inferred] This distinction has therapeutic relevance, as anti-TSLP (tezepelumab) and anti-IL-4Rα (dupilumab) target different nodes of type 2 inflammation. [Model Knowledge]
- **VWF absence**: ADAMTS13 is present while its primary substrate, VWF, is absent. [KG Evidence] This is biologically expected because ADAMTS13 cleaves VWF, establishing an inverse functional relationship; WGCNA modules capture positive co-expression, so VWF would segregate into a different module. [Model Knowledge] This confirms the module captures ADAMTS13 in its regulatory context rather than a simple coagulation cassette. [Inferred]

### 4. Biological Themes

#### 4.1 Unifying Theme: Inflammatory Metabolic Stress with Epithelial Barrier Disruption

The Lightyellow module integrates three biological programs whose co-expression implies a coordinated systemic state:

**Program 1: Gamma-glutamyl cycle and glutathione catabolism.**
The metabolite members 5-oxoproline, cysteinylglycine, cysteine-glutathione disulfide, and cysteine s-sulfate define the degradation arm of the gamma-glutamyl cycle. [KG Evidence] Three of these metabolites share the glutathione metabolic process pathway (GO:0006749). [KG Evidence] The pyroglutamyl-dipeptides (pyroglutamylglutamine, pyroglutamylvaline, pyroglutamylleucine) further implicate gamma-glutamyl transpeptidase activity, as pyroglutamic acid (5-oxoproline) is a byproduct of the gamma-glutamyl cycle and serves as the N-terminal moiety of these dipeptides. [Model Knowledge]

**Program 2: Glycolytic flux and energy metabolism.**
Pyruvate and lactate represent the terminal steps of glycolysis; their shared pathway bridge through LDHA (NCBIGene:3939) confirms coordinated glycolytic regulation. [KG Evidence] The LDHA bridge connects 2 input entities in the pathway enrichment analysis. [KG Evidence] Lactate production is mechanistically linked to inflammasome activation, as demonstrated by studies showing that lactic acid fermentation is required for NLRP3 inflammasome activation and IL-1 family cytokine processing (2021; 2026). [Literature]

**Program 3: Innate alarmin and cytokine signaling.**
TSLP, IL1A, and IL5 converge on hemopoiesis, cytokine-mediated signaling, and inflammatory response pathways. [KG Evidence] NRTN (neurturin) adds a neurotrophic dimension, sharing cell-cell signaling (GO:0007267), cell differentiation (GO:0030154), and cell proliferation regulation (UMLS:C1156235) with the immune members. [KG Evidence] The response-to-stress pathway (GO:0006950) connects 4 of 5 protein members (ADAMTS13, IL5, NRTN, TSLP), suggesting the module is activated under stress conditions. [KG Evidence]

#### 4.2 Hub-Filtered Insights

After de-emphasizing IL1A (5,816 edges; flagged as hub), the most informative pathway and disease associations are those contributed by moderate-connectivity members. The glutathione metabolic process (GO:0006749) shared by ornithine (848 edges), 5-oxoproline (404 edges), and cysteinylglycine (68 edges) represents a hub-free convergence point. [KG Evidence] Similarly, the ADAMTS13-specific associations with hemostasis, platelet activation, and blood coagulation (all Tier 1) are anchored by a well-characterized but non-hub entity (2,517 edges). [KG Evidence]

#### 4.3 One-Carbon and Sulfur Amino Acid Metabolism

S-adenosylhomocysteine (SAH) anchors the one-carbon metabolism axis of the module. [KG Evidence] SAH is the product of methyltransferase reactions that consume S-adenosylmethionine (SAM), and it is the direct precursor to homocysteine via SAH hydrolase. [Model Knowledge] The transsulfuration pathway converts homocysteine to cysteine, which feeds glutathione biosynthesis. [Model Knowledge] The module thus captures the downstream metabolic consequences of active methylation and transsulfuration: SAH accumulation as a methylation byproduct, followed by efficient conversion through homocysteine and cysteine (both absent, indicating rapid flux) to glutathione degradation products (present). [Inferred]

#### 4.4 Urea Cycle and Pyrimidine Catabolism

Ornithine serves as both a urea cycle intermediate and a polyamine precursor. [Model Knowledge] Its presence alongside 3-ureidopropionate (N-carbamoyl-beta-alanine), a pyrimidine catabolism intermediate, suggests nitrogen disposal and nucleotide metabolism as a secondary theme. [KG Evidence] [Model Knowledge] The LACC1-NOS2-polyamine axis described in inflammatory macrophages (Nature, 2022) provides a mechanistic link between ornithine metabolism and the inflammatory program captured by the module's cytokine members. [Literature]

### 5. Gap Analysis

#### 5.1 Informative Absences (Open World Assumption)

The following absences carry analytical significance; they are interpreted as "unstudied" or "uninformative for this module," not as evidence of non-existence:

| Expected Entity | Interpretation | Significance |
|---|---|---|
| Glutathione (GSH) | Rapid catabolism; degradation products present; intact GSH likely depleted. | Indicates net oxidative stress or active GGT-mediated turnover. [Inferred] |
| Homocysteine | Efficient transsulfuration flux; downstream cysteine derivatives present. | Suggests functional CBS/CTH pathway; not a hyperhomocysteinemia signature. [Inferred] |
| Free cysteine | Rapid utilization into GSH, oxidized forms, and conjugates. | Consistent with active redox cycling. [Inferred] |
| IL-4, IL-13 | TSLP-driven innate alarmin axis rather than classical Th2. | Module may capture epithelial barrier inflammation distinct from adaptive Th2. [Inferred] |
| VWF | Anti-correlates with ADAMTS13 (substrate-enzyme relationship). | Confirms module captures ADAMTS13 regulatory context. [Inferred] |
| GGT1 (enzyme) | Likely absent from proteomics panel (membrane-bound enzyme). | Technical gap; GGT activity is strongly implicated by metabolite profile. [Inferred] |

#### 5.2 Standard Gaps

- **Glutamate**: high-flux metabolite with too many pathway memberships to co-express tightly with this module. [Inferred]
- **Methionine**: dietary-supply-driven variation likely decouples it from enzymatic co-expression patterns. [Inferred]
- **Taurine**: high basal plasma concentration with limited inter-individual variation. [Inferred]

#### 5.3 Cold-Start Entities

3-Amino-2-piperidone (resolved as 3,4-dihydro-2-pyridone; UNII:T0LO6RP873) has zero KG edges and was resolved with only 70% confidence via fuzzy matching. [KG Evidence] Semantic similarity search identified pyridone analogues (3,4-dihydro-6-methyl-2-pyridone, 93% similarity; 3,5-dimethyl-2-pyridone, 89% similarity) but yielded no biologically actionable inferred connections. [KG Evidence] This entity requires manual curation to confirm identity and pathway membership.

### 6. Temporal Context

No longitudinal design metadata was provided for the Lightyellow module. The following causal architecture is inferred from the biochemical directionality of the pathways represented:

**Upstream (likely causes):**
- TSLP and IL1A signaling represent early alarmin responses to epithelial barrier disruption or microbial challenge. [Model Knowledge] IL1A is a "dual-function" cytokine released from damaged epithelial cells. [Model Knowledge]
- Glycolytic reprogramming (pyruvate → lactate conversion) is an early consequence of inflammatory activation, as required for NLRP3 inflammasome assembly. [Literature] (Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation, 2021)

**Downstream (likely consequences):**
- Glutathione catabolism products (cysteinylglycine, cysteine-glutathione disulfide, 5-oxoproline) accumulate downstream of inflammatory oxidative stress. [Model Knowledge]
- ADAMTS13 consumption or downregulation occurs as a consequence of systemic inflammation; reduced ADAMTS13 activity contributes to thrombotic microangiopathy. [Model Knowledge]
- IL5 production and eosinophilic activation represent a later-phase type 2 response. [Model Knowledge]

**Causal inference opportunity**: A longitudinal study measuring these analytes at multiple time points could test whether TSLP/IL1A elevations precede glutathione depletion (as measured by increased cysteinylglycine and decreased GSH:GSSG ratio) and whether these metabolic shifts precede ADAMTS13 decline and IL5 elevation. [Inferred]

### 7. Research Recommendations

#### 7.1 High Priority: Experimental Validations

1. **Measure glutathione (GSH) and oxidized glutathione (GSSG) in the study cohort.** The module's metabolite profile strongly predicts that GSH/GSSG ratio will inversely correlate with module eigengene values. This is the single most informative missing measurement. [Inferred]

2. **Test cysteine-glutathione disulfide as a substrate for GSTP1 and GSTA1.** The Tier 3 prediction of physical interaction with glutathione S-transferases (Section 3.1) is biochemically plausible and testable via standard enzymatic assays. [Inferred]

3. **Assess GGT enzymatic activity in the cohort.** Although GGT protein may not be on the proteomics panel, serum GGT activity (a routine clinical assay) should correlate with this module if gamma-glutamyl cycle turnover is indeed driving the metabolite signature. [Inferred]

#### 7.2 Moderate Priority: Targeted Literature and Database Searches

4. **Search metabolomics databases for pyroglutamylvaline in colorectal cancer cohorts.** Two structural analogues converge on this disease association (Section 3.2); a targeted HMDB/MetaboAnalyst query could confirm or refute the prediction before any wet-lab investment. [Inferred]

5. **Investigate whether the TSLP-IL5 axis (without IL-4/IL-13) defines a distinct immune endotype.** Cross-reference the module membership against published single-cell RNA-seq atlases from epithelial barrier tissues (skin, gut, airway) to determine whether TSLP-IL5 co-expression without IL-4/IL-13 recapitulates a known innate lymphoid cell (ILC2) or alarmin-driven signature. [Inferred]

6. **Confirm the identity of 3-amino-2-piperidone.** The 70% confidence fuzzy match to 3,4-dihydro-2-pyridone requires mass spectral verification (retention time, MS/MS fragmentation) against an authentic standard. [KG Evidence]

#### 7.3 Lower Priority: Follow-Up Analyses

7. **Perform conditional association analysis between ADAMTS13 and lactate.** The multiple 2-hop disease-mediated paths (Section 2.3) suggest that their co-expression may be confounded by shared cardiovascular disease status; conditioning on cardiovascular endpoints would test whether their correlation is independent. [Inferred]

8. **Test module preservation across independent cohorts.** The Lightyellow module should be evaluated for preservation in external metabolomics-proteomics datasets (e.g., the Framingham Heart Study or UK Biobank) to assess whether the inflammatory-metabolic program it encodes is robust or cohort-specific. [Inferred]

9. **Assess 1-palmitoylglycerol's role in ether lipid metabolism.** The cold-start inference linking this monoacylglycerol to AGPS and Reactome ether lipid pathways (Section 3.3) can be triaged by checking LIPID MAPS for MG(16:0) annotations before committing to enzymatic validation. [Inferred]

---

*Report generated from KRAKEN knowledge graph analysis of the Lightyellow WGCNA module (19 entities: 5 proteins, 14 metabolites). All evidence attributions are tagged per the attribution protocol: [KG Evidence] for direct knowledge graph findings, [Literature] for grounded abstracts, [Model Knowledge] for general biomedical knowledge, and [Inferred] for derived conclusions. Hub bias warnings apply to IL1A (5,816 edges). Approximately 18% of Tier 3 computational predictions advance to clinical investigation.*

### Literature References

Papers discovered via semantic search. 7 unique papers across 3 hypotheses.

| Hypothesis | Citation | Link | Relevance |
|------------|----------|------|-----------|
| Bridge: Gene → SmallMolecule (2 hops) |  (2022) "Frontiers \| Metabolic Engineering of Bacillus amyloliquefaciens to Efficiently Synthesize L-Ornithin..." | [Link](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.905110/full) | amyloliquefaci ... were enhanced by ... . The glutamate degradation pathway, the precursor ... pathway, the L-ornithine... |
| Bridge: Gene → SmallMolecule (2 hops) |  (2021) "Frontiers \| Ornithine Transcarbamylase – From Structure to Metabolism: An Update" | [Link](https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.748249/full) | Ornithine transcarbamylase (OTC; EC 2.1.3.3) is a ubiquitous enzyme found in almost all organisms, including vertebrates... |
| Bridge: Gene → MolecularMixture (1 hops) |  (2026) "Lactic acid drives NLRP3 inflammasome activation and caspase-1–like cytokine cleavage via intracellu..." | [Link](https://www.nature.com/articles/s41419-026-08708-y) | Glycolysis is critical for NLRP3 inflammasome activation, yet the link between lactic acid metabolism and inflammasome s... |
| Bridge: Gene → MolecularMixture (1 hops) |  (2021) "Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation" | [Link](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.630380/full) | mechanism was a ... pathway of NLRP3 inflam ... ome regulation, we further ... effect of GSK2 ... 37808A on IL-1 ... oth... |
| Bridge: Gene → SmallMolecule (2 hops) |  (2013) "Metabolic evolution of Corynebacterium glutamicum for increased production of L-ornithine \| BMC Biot..." | [Link](https://link.springer.com/article/10.1186/1472-6750-13-47) | . These are the reactions catalysed by ... rate dehydrogenase, ... -dependent N-acetyl- ... -glutamyl-phosphate reductas... |
| Bridge: Gene → MolecularMixture (2 hops) |  (2023) "Protein-metabolite interactomics of carbohydrate metabolism reveal regulation of lactate dehydrogena..." | [Link](https://pubmed.ncbi.nlm.nih.gov/36893255/) | (A) Volcano plots ... (black) and ... (pink). Specific, significant metabolites are numbered and labeled. Stars indicate... |
| Bridge: Gene → MolecularMixture (2 hops) |  (2023) "The role of lactate in cardiovascular diseases \| Cell Communication and Signaling \| Springer Nature ..." | [Link](https://link.springer.com/article/10.1186/s12964-023-01350-7) | . They include ... FX-11, GSK2837808 ... of LDH, such ... stiripent ... , galloflfl ... hydroxyindoles, ... 101 (gossyp... |